上学，对于小石头这家人来说，曾经是个遥不可及的梦想。小石头是一个脊髓性肌萎缩症患儿，确诊时被医生告知有可能活不到两岁，并且当时国内无药可 治。不幸中的万幸是，在小石头寻医问药的这五年间，两次国家医保药品目录谈判让小石头跨过了生死的门槛，也让小石头开始了全新的生活。今年9月， 小石头在社会各界的关怀下，顺利地升入小学。面对新的生活，这个被疾病折磨了七年多但同时又被不幸和幸运同时眷顾的孩子和家庭怎样了？ 小石头出生于2018年3月，今年7岁半。刚出生时小石头和其他的孩子一样，可爱健康。但8个月后，和同龄的孩子相比，小石头的发育出现了问题。在辗转 了多家医院后，一个医生根据经验判断这个孩子可能得了罕见病SMA，也就是脊髓性肌萎缩症。 2021年新一轮医保药品目录谈判开始启动。诺西那生钠的药企主动申报，进入了医保谈判。罕见病药品用量很小但研发投入巨大，价格从55万降到3万，医 保目录谈判的难度可想而知，被网友们称为"灵魂砍价"的医保目录谈判，就是希望通过国家的力量在患者，企业和医保基金中搭建平台，找到最佳平衡点。 石头爸爸说那一瞬间，他和妻子都感到了绝望。因为根据之前查到的资料，这个罕见病在当时的国内还没有特效药。一 ...

Group 1 - The core viewpoint of the article highlights the recent stock performance of 基石药业-B (02616), which saw an increase of nearly 5%, closing at 9.52 HKD with a trading volume of 78.05 million HKD [1] - Singapore's Government Investment Corporation (GIC Private Limited) increased its stake in 基石药业 by acquiring 80.4 million shares at an average price of 7.9 HKD per share, totaling approximately 635 million HKD, raising its ownership from 0.00% to 5.49% [1] - 基石药业 reported a significant decline in revenue for the first half of the year, amounting to 49.45 million RMB, a year-on-year decrease of 80.54%, while R&D expenses rose by 58.75% to 105 million RMB, resulting in a loss of 270 million RMB [1] Group 2 - The company announced a price adjustment for its drug 普拉替尼 in preparation for negotiations regarding the national medical insurance drug list, with expectations that inclusion in the list could lead to sales growth benefits starting in 2026, offsetting short-term revenue impacts [1] - In the first half of 2025, the company did not enter into any significant external licensing agreements, but it signed a major external licensing agreement with Gentili in July 2025, anticipating revenue from licensing fees in the second half of 2025 [1]

Group 1 - The stock of Basilea Pharmaceutica (02616) increased by nearly 5%, reaching HKD 9.52 with a trading volume of HKD 78.05 million [1] - Singapore's Government Investment Corporation (GIC Private Limited) increased its stake in Basilea by acquiring 80.4 million shares at an average price of HKD 7.9, totaling approximately HKD 635 million, raising its ownership from 0.00% to 5.49% [1] - Basilea reported a mid-year revenue of RMB 49.45 million, a year-on-year decrease of 80.54%, while R&D expenses rose by 58.75% to RMB 105 million, resulting in a loss of RMB 270 million [1] Group 2 - The company is preparing for negotiations regarding the National Medical Insurance Drug List, adjusting the price of its drug, Pralsetinib [1] - If Pralsetinib is included in the National Medical Insurance List, the expected sales growth from 2026 onwards is anticipated to offset the short-term negative impact on revenue [1] - In the first half of 2025, the company did not enter into any significant external licensing agreements, but it signed a major external licensing agreement with Gentili in July 2025, expecting to receive licensing fee income in the second half of 2025 [1]